Physician profile
Jonathan A Cropp
NPI 1063859643
$475.23
in general payments reported to CMS, 2019-2025
11 companies · $47.19 in 2025
The $47.19 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $38.09 · 2022: $90.79 · 2023: $256 · 2024: $43.23 · 2025: $47.19.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $346.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $346.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $150.95 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $142.74 | 2021-2023 | |
| Lilly USA, LLC | $44.28 | 2022-2023 | Mounjaro, Trulicity, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $28.33 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $24.05 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.82 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.98 | 2023 | |
| Abbott Laboratories | $16.89 | 2023 | Freestyle Libre 3 |
| Neurocrine Biosciences, INC. | $14.99 | 2023 | Ingrezza |
| Amgen INC. | $14.53 | 2023 | Otezla |
| Genentech USA, INC. | $2.67 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Cropp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.